A review finds genetic therapies improved several ALS measures in rodent studies
Original source
Exploring Genetic Therapies Targeting Amyotrophic Lateral Sclerosis in Animal Models: A Systematic Review and Meta-Analysis. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Study type
- Systematic review
- Studied in
- Human, Animal
A systematic review and meta-analysis found that genetic therapies improved most analysed outcomes in rodent models of amyotrophic lateral sclerosis (ALS), including motor-neuron counts, survival and motor function. The review included 53 studies published from 2015 to 2025, but the authors reported a high risk of bias in the preclinical evidence.
Why this matters
The findings support further research into genetic therapies for ALS. They do not show that these treatments work in people or change treatment options now, because the evidence came from animal studies and needs confirmation in higher-quality research before clinical translation.
Limitations and context
This was a preclinical systematic review and meta-analysis, not a clinical trial. The 53 included studies had a high risk of bias, and the authors said further high-quality studies are needed. The review was published on 18 August 2026; no information about independent replication or human testing was provided in the source.